Other scientific trials in sufferers with non-Hodgkin's lymphoma [24] and sufferers with Innovative malignancy [14] have shown also that zosuquidar didn't noticeably influence the pharmacokinetics of doxorubicin and had moderate consequences to the pharmacokinetics of vincristine. These medical trials approved that zosuquidar could properly adminis